One-year Thyroglobulin Levels as a Predictive Measure for Recurrence and Need for Continued Surveillance in Treated Differentiated Thyroid Cancer
Authors' conclusion
One year after treatment of DTC, TG levels <0.5 ng/mL, in the absence of TGab, are associated with an exceedingly low risk of recurrence suggesting that further surveillance may not be warranted.
Study context
- Population
- Patients with differentiated thyroid cancer (DTC) treated surgically with or without adjuvant radioiodine therapy, followed with standard American Thyroid Association surveillance
- Participants
- 268 patients
- Exposure
- Undetectable thyroglobulin (TG) vs detectable TG vs positive thyroglobulin antibody (TGab) at 1 year posttreatment
- Undetectable TGn = 210reference
- Detectable TGn = 29
- Positive TGabn = 29
- Outcome
- Structural recurrence rate
Main finding
As reported in the abstract
Structural recurrence
- Overall structural recurrence
- 18/268 (7%)
Observational data: associations, not effects.
Further findings
- Conversion to undetectable TG without additional treatment · last follow-up — Detectable TG
- 38%
- Resolution of TGab and undetectable TG without additional treatment · last follow-up — Positive TGab
- 21%
- Undetectable TG at last follow-up
- 93% · 196 of 210
Original publication
One-year Thyroglobulin Levels as a Predictive Measure for Recurrence and Need for Continued Surveillance in Treated Differentiated Thyroid Cancer. Endocr Pract. Published 4 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →